Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.

Endocrinology, diabetes & metabolism

Crossing the line: BMI category changes with tirzepatide.

American journal of preventive cardiology

Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report.

JAAD case reports

Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles.

Annals of surgery

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.

Journal of endocrinological investigation

Leucine supplementation modulates body composition and early weight rebound during GLP-1 receptor agonist therapy in diet-induced obese mice.

Journal of endocrinological investigation

Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.

Gynecologic oncology

Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.

Cardiovascular revascularization medicine : including molecular interventions

BEST PEPTIDES: S-Tier: Tirzepatide, Tesamorelin, Oxytocin A-Tier: Semaglutide, Sermorelin, Melanotan 1 B-Tier: NAD+ C-Tier: Everything else due to purity issues, until they can be legally compounded by US pharmacies (e.g. Retatrutide, BPC-157, TB-4, CJC, MT2, MOTS-c, etc.)

SKIP HYPE: If you want to HEAL faster, Skip BPC-157 (poor data) Take a Growth Hormone peptide (TESAMORELIN) If you want to lose FAT, Skip Reta (stimulates the heart) Take a GLP-1/GIP (TIRZEPATIDE) If you want to feel CALM, Skip Selank (poor data) Take a neuropeptide (OXYTOCIN)

@TheLongInvest For now, it's $HIMS. But I suspect it'll be $AVCT #AVCT in the not-too-distant future. The large majority of US retail associate #peptides with the GLP-1 mimetics (semaglutide, tirzepatide) and bioregulatory / research peptides (e.g. BPC-157; TB-500; GHK-Cu, etc.). But the

🚨 $HIMS +46% in 1 week as FDA schedules peptide compounding review (July 23–24) The FDA will evaluate 7 peptides for compounding eligibility: → BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon ✅Hims & Hers CMO called it an “avenue toward trusted channels” This is https://t.co/yKIFM6lEZh

Did a bit of research and seems like these are most used peptides: -tirzepatide -semaglutide -BPC-157 -TB-500 -ipamorelin What do you think of peptides?

🚨 $KITL BULLISH ALERT: FDA Peptide Reversal = Massive Catalyst for the OTC Pioneer! With RFK Jr. at HHS and the FDA now actively weighing the lift on restrictions for ~14 key peptides (BPC-157, TB-500, CJC-1295, GHK-Cu, and more), the gray-market peptide era is ending — and

• HHS Secretary Kennedy just announced the FDA is removing 12 key peptides from Category 2 restrictions starting with BPC-157 and others moving to full scientific review. • $HIMS is not a GLP-1 only company. The entire peptide industry stands ready to boom as regulated access https://t.co/3HzcTJWfS0 https://t.co/9UySm2FWBU

Common GLP 1 agents: •Semaglutide (Ozempic, Wegovy) •Liraglutide (Victoza, Saxenda) •Dulaglutide (Trulicity) •Exenatide (Byetta, Bydureon) •Tirzepatide (Mounjaro, Zepbound), a dual GLP-1 and GIP agonist with greater potency